Nrx Pharmaceuticals Inc (NRXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -25,126 | -30,150 | -39,754 | -93,063 | -51,777 |
| Depreciation Amortization | 5 | 5 | 4 | 2 | 19 |
| Accounts receivable | N/A | N/A | N/A | 831 | -831 |
| Other Working Capital | 5,291 | 5,164 | 699 | -4,898 | 3,453 |
| Other Operating Activity | 9,193 | 3,324 | -704 | 59,425 | 46,871 |
| Operating Cash Flow | $-10,637 | $-21,657 | $-39,755 | $-37,703 | $-2,265 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -3 | -10 | -7 | -2 |
| Investing Cash Flow | $N/A | $-3 | $-10 | $-7 | $-2 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 7,079 | 943 | 10,020 | N/A | 620 |
| Debt Repayment | -8,575 | -4,035 | -518 | -176 | N/A |
| Common Stock Issued | 5,911 | 8,122 | 22,712 | 53,682 | 2,579 |
| Other Financing Activity | 3,070 | 1,171 | 0 | 9,950 | 50 |
| Financing Cash Flow | $7,485 | $6,201 | $32,214 | $63,456 | $3,249 |
| Beginning Cash Position | 4,595 | 20,054 | 27,605 | 1,859 | 877 |
| End Cash Position | 1,443 | 4,595 | 20,054 | 27,605 | 1,859 |
| Net Cash Flow | $-3,152 | $-15,459 | $-7,551 | $25,746 | $982 |
| Free Cash Flow | |||||
| Operating Cash Flow | -10,637 | -21,657 | -39,755 | -37,703 | -2,265 |
| Capital Expenditure | N/A | -3 | -10 | -7 | -2 |
| Free Cash Flow | -10,637 | -21,660 | -39,765 | -37,710 | -2,267 |